Abstract
The disposition of (+)- and (-)-propranolol was determined after chronic as compared to single oral doses of racemic drug. Single oral doses (80 mg) of a stable isotope-labeled pseudoracemate were given to six dogs before and after chronic pretreatment with unlabeled propranolol. The bioavailability of (-)-propranolol (5.7 +/- 1.6%; mean +/- S.E.) was considerably lower (P less than .01) than that of (+)-propranolol (16.1 +/- 5.9%) after single doses. Chronic pretreatment led to a 167% increase in the bioavailability of (-)-propranolol to 15.2 +/- 3.7% (P less than .01), with only a 47% increase in (+)-propranolol to 23.7 +/- 4.5% (N.S.). Chronic pretreatment had no effect on the kinetics of i.v. doses of tritium-labeled racemic drug administered simultaneously or on blood binding. This stereoselective increase in the bioavailability of (-)-propranolol was associated with an unexpected 62% increase in the glucuronidation of this enantiomer (P less than .01) with no effect on the glucuronidation of (+)-propranolol. There was, however, a change in the stereochemical composition of 4'-hydroxypropranolol from single doses, (-)/(+)-enantiomer ratio 1.37 +/- 0.14, to chronic doses, 1.23 +/- 0.13 (P less than 0.05), suggesting stereoselective inhibition of ring-oxidation of (-)-propranolol. This study demonstrates preferential presystemic hepatic removal of (-)-propranolol in the dog by a process, probably ring-oxidation, that becomes partially inhibited after chronic doses, leading to a stereoselective increase in the bioavailability of this enantiomer.
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|